Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1968 1
1973 1
1974 2
1976 1
1983 1
1984 1
1985 1
1986 1
1992 1
1994 1
1995 2
1996 7
1998 4
1999 1
2000 1
2001 2
2002 1
2003 3
2004 3
2005 3
2006 1
2007 5
2008 2
2009 1
2010 4
2011 10
2012 9
2013 12
2014 13
2015 11
2016 20
2017 13
2018 9
2019 7
2020 16
2021 14
2022 14
2023 16
2024 10
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

198 results

Results by year

Filters applied: . Clear all
Page 1
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction.
Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, Lam CSP, Ponikowski P, Voors AA, Jia G, McNulty SE, Patel MJ, Roessig L, Koglin J, O'Connor CM; VICTORIA Study Group. Armstrong PW, et al. N Engl J Med. 2020 May 14;382(20):1883-1893. doi: 10.1056/NEJMoa1915928. Epub 2020 Mar 28. N Engl J Med. 2020. PMID: 32222134 Free article. Clinical Trial.
Features and Outcomes of Histologically Proven Myocarditis With Fulminant Presentation.
Kanaoka K, Onoue K, Terasaki S, Nakano T, Nakai M, Sumita Y, Hatakeyama K, Terasaki F, Kawakami R, Iwanaga Y, Miyamoto Y, Saito Y; Japanese Registry of Fulminant Myocarditis Investigators. Kanaoka K, et al. Circulation. 2022 Nov 8;146(19):1425-1433. doi: 10.1161/CIRCULATIONAHA.121.058869. Epub 2022 Sep 27. Circulation. 2022. PMID: 36164974
Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event: Insights From the VICTORIA Trial.
Lam CSP, Giczewska A, Sliwa K, Edelmann F, Refsgaard J, Bocchi E, Ezekowitz JA, Hernandez AF, O'Connor CM, Roessig L, Patel MJ, Pieske B, Anstrom KJ, Armstrong PW; VICTORIA Study Group. Lam CSP, et al. JAMA Cardiol. 2021 Jun 1;6(6):706-712. doi: 10.1001/jamacardio.2020.6455. JAMA Cardiol. 2021. PMID: 33185650 Free PMC article. Clinical Trial.
High-Dose Versus Low-Dose Pitavastatin in Japanese Patients With Stable Coronary Artery Disease (REAL-CAD): A Randomized Superiority Trial.
Taguchi I, Iimuro S, Iwata H, Takashima H, Abe M, Amiya E, Ogawa T, Ozaki Y, Sakuma I, Nakagawa Y, Hibi K, Hiro T, Fukumoto Y, Hokimoto S, Miyauchi K, Yamazaki T, Ito H, Otsuji Y, Kimura K, Takahashi J, Hirayama A, Yokoi H, Kitagawa K, Urabe T, Okada Y, Terayama Y, Toyoda K, Nagao T, Matsumoto M, Ohashi Y, Kaneko T, Fujita R, Ohtsu H, Ogawa H, Daida H, Shimokawa H, Saito Y, Kimura T, Inoue T, Matsuzaki M, Nagai R. Taguchi I, et al. Circulation. 2018 May 8;137(19):1997-2009. doi: 10.1161/CIRCULATIONAHA.117.032615. Circulation. 2018. PMID: 29735587 Free PMC article. Clinical Trial.
A novel ryanodine receptor 2 inhibitor, M201-A, enhances natriuresis, renal function and lusi-inotropic actions: Preclinical and phase I study.
Kaneko N, Loughrey CM, Smith G, Matsuda R, Hasunuma T, Mark PB, Toda M, Shinozaki M, Otani N, Kayley S, Da Silva Costa A, Martin TP, Dobi S, Saxena P, Shimamoto K, Ishikawa T, Kambayashi R, Riddell A, Elliott EB, McCarroll CS, Sakai T, Mitsuhisa Y, Hirano S, Kitai T, Kusano K, Inoue Y, Nakamura M, Kikuchi M, Toyoda S, Taguchi I, Fujiwara T, Sugiyama A, Kumagai Y, Iwata K. Kaneko N, et al. Among authors: taguchi i. Br J Pharmacol. 2024 Sep;181(18):3401-3419. doi: 10.1111/bph.16379. Epub 2024 May 21. Br J Pharmacol. 2024. PMID: 38773354 Clinical Trial.
Eicosapentaenoic Acid Added to Strong Statin Therapy.
Nakahara S, Komatsu T, Taguchi I. Nakahara S, et al. Among authors: taguchi i. Circ J. 2016;80(2):321-2. doi: 10.1253/circj.CJ-15-1352. Epub 2015 Dec 25. Circ J. 2016. PMID: 26725768 Free article. No abstract available.
In-hospital initiation of angiotensin receptor-neprilysin inhibition in acute heart failure: the PREMIER trial.
Tanaka A, Kida K, Matsue Y, Imai T, Suwa S, Taguchi I, Hisauchi I, Teragawa H, Yazaki Y, Moroi M, Ohashi K, Nagatomo D, Kubota T, Ijichi T, Ikari Y, Yonezu K, Takahashi N, Toyoda S, Toshida T, Suzuki H, Minamino T, Nogi K, Shiina K, Horiuchi Y, Tanabe K, Hachinohe D, Kiuchi S, Kusunose K, Shimabukuro M, Node K. Tanaka A, et al. Among authors: taguchi i. Eur Heart J. 2024 Nov 8;45(42):4482-4493. doi: 10.1093/eurheartj/ehae561. Eur Heart J. 2024. PMID: 39215531 Free PMC article. Clinical Trial.
Treatment of Young Women with Acute Myocardial Infarction.
Mizutani Y, Ishikawa T, Nakahara S, Taguchi I. Mizutani Y, et al. Among authors: taguchi i. Intern Med. 2021 Jan 15;60(2):159-160. doi: 10.2169/internalmedicine.5883-20. Epub 2020 Sep 12. Intern Med. 2021. PMID: 32921694 Free PMC article. No abstract available.
Rationale and design of an investigator-initiated, multicenter, prospective, placebo-controlled, double-blind, randomized trial to evaluate the effects of finerenone on vascular stiffness and cardiorenal biomarkers in type 2 diabetes and chronic kidney disease (FIVE-STAR).
Tanaka A, Shibata H, Imai T, Yoshida H, Miyazono M, Takahashi N, Fukuda D, Okada Y, Teragawa H, Suwa S, Kida K, Moroi M, Taguchi I, Toyoda S, Shimabukuro M, Tanabe K, Tanaka K, Nangaku M, Node K; FIVE-STAR trial investigators. Tanaka A, et al. Among authors: taguchi i. Cardiovasc Diabetol. 2023 Jul 31;22(1):194. doi: 10.1186/s12933-023-01928-y. Cardiovasc Diabetol. 2023. PMID: 37525257 Free PMC article. Clinical Trial.
198 results